Novartis AG Release: First Myelofibrosis Medication For Life-Threatening Blood Cancer Approved In Singapore

Singapore, May 15, 2014 - (ACN Newswire) - Novartis announced today, the launch of Jakavi, the first and only approved oral medication to treat patients suffering from myelofibrosis in Singapore, and across more than 50 countries. Jakavi(R) (INC 424, ruxolitinib) is a JAK 1 and JAK 2 inhibitor for the treatment of disease-related splenomegaly and/or symptoms in adult patients with myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Help employers find you! Check out all the jobs and post your resume.